Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Keith D. Lillemoe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0004-5057-3875; OpenAlex author ID A5051782291. Sources: OpenAlex.

Their work

Papers
91 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
263
Papers, trials and grants by year

2011: 4 papers · 2012: 3 papers · 2013: 4 papers · 2014: 4 papers · 2015: 5 papers · 2016: 2 papers · 2017: 9 papers · 2018: 6 papers · 2019: 5 papers · 2020: 13 papers · 2021: 7 papers · 2022: 8 papers · 2023: 4 papers · 2024: 7 papers · 2025: 6 papers · 2026: 4 papers

Papers 50 of 91

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358↗
  3. Lymph Node Yield Is Associated With Improved Overall Survival and Increased Time to Recurrence in Node-Negative Pancreatic Ductal Adenocarcinoma Following Neoa… Co-author DOI 10.1097/sla.0000000000006432↗
  4. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000007214↗
  5. Preoperative Biopsy Is Not Associated With Adverse Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Upfront Resection. Co-author DOI 10.1016/j.jss.2025.01.007↗
  6. Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2025.109647↗
  7. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… Co-author DOI 10.1097/sla.0000000000006322↗
  8. Efficacy of Neoadjuvant Therapy and the Prognostic Significance of Serum Carcinoembryonic Antigen Level in Patients with Localized Pancreatic Adenocarcinoma wi… Co-author DOI 10.1097/sla.0000000000006719↗
  9. Operation Alone for Resectable Pancreatic Adenocarcinoma: Should We Operate if Multimodal Treatment Is Off the Table? Co-author DOI 10.1097/xcs.0000000000001464↗
  10. Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5. Co-author DOI 10.1158/2767-9764.crc-24-0392↗
  11. Common hepatic artery lymph node metastasis in pancreatic ductal adenocarcinoma: an analysis of actual survival. Co-author DOI 10.1016/j.gassur.2024.02.018↗
  12. Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.09.041↗
  13. The impact of surgical-oncologic textbook outcome in patients with stage I to III pancreatic ductal adenocarcinoma: A cross-validation study of two national re… Co-author DOI 10.1016/j.surg.2023.11.004↗
  14. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrosp… Co-author DOI 10.1016/j.surg.2024.01.008↗
  15. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment. Co-author DOI 10.1097/sla.0000000000005874↗
  16. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006131↗
  17. Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0489↗
  18. Portal Vein or Superior Mesenteric Vein Thrombosis with Dose-Escalated Radiation for Borderline or Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-023-05796-5↗
  19. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. Co-author DOI 10.1016/j.ejca.2023.113293↗
  20. Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Receive Neoadjuvant Therapy. Co-author DOI 10.1097/sla.0000000000005354↗
  21. Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. Co-author DOI 10.1097/xcs.0000000000000499↗
  22. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemor… Co-author DOI 10.1007/s00330-021-08304-y↗
  23. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  24. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancre… Co-author DOI 10.1016/j.surg.2022.05.024↗
  25. A Lesson in Transcriptional Plasticity: Classical Identity Is Silenced, but Not Lost, in Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.1053/j.gastro.2022.07.005↗
  26. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  27. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004552↗
  28. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004585↗
  29. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria. Co-author DOI 10.1097/sla.0000000000005433↗
  30. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/bjs.12003↗
  31. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-020-04897-9↗
  32. Preoperative cholangitis is an independent risk factor for mortality in patients after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.07.025↗
  33. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Co-author DOI 10.1093/jnci/djaa073↗
  34. Reassessing the Role for Sympathetic Neurolysis in Patients with Pancreatic Cancer. Last author DOI 10.1097/aln.0000000000003880↗
  35. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1039↗
  36. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoad… Co-author DOI 10.1245/s10434-020-09444-z↗
  37. Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.03.035↗
  38. Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic ca… Co-author DOI 10.1016/j.pan.2019.10.007↗
  39. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. Co-author DOI 10.1016/j.pan.2020.03.011↗
  40. Primary and Metastatic Pancreatic Cancer Cells Exhibit Differential Migratory Potentials. Co-author DOI 10.1097/mpa.0000000000001459↗
  41. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001590↗
  42. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003123↗
  43. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. Co-author DOI 10.1111/his.14067↗
  44. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. Co-author DOI 10.1111/his.14086↗
  45. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-20-0439↗
  46. Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08040-0↗
  47. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoad… Co-author DOI 10.1245/s10434-019-08084-2↗
  48. Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08354-4↗
  49. FOLFIRINOX Versus Gemcitabine-based Therapy for Pancreatic Ductal Adenocarcinoma: Lessons from Patient-derived Cell Lines. Co-author DOI 10.21873/anticanres.14355↗
  50. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical… Co-author DOI 10.1001/jamaoncol.2019.0892↗

Closest collaborators

The 25 strongest of 263 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Motaz Qadan · 44 shared papers, 2018–2026 · strength 6.57
  2. Cristina Rosa Ferrone · 58 shared papers, 2012–2026 · strength 5.93
  3. Carlos F. Fernandez-del Castillo · 49 shared papers, 2012–2025 · strength 5.28
  4. Andrew Louis Warshaw · 34 shared papers, 2012–2025 · strength 3.33
  5. Theodore Sunki Hong · 32 shared papers, 2013–2026 · strength 3.26
  6. Carlos Fernández-del Castillo · 24 shared papers, 2013–2026 · strength 3.17
  7. Jennifer Yon-Li Wo · 27 shared papers, 2013–2026 · strength 2.93
  8. David P. Ryan · 24 shared papers, 2013–2026 · strength 2.27
  9. Thomas P. Hank · 13 shared papers, 2020–2025 · strength 1.75
  10. Lawrence Scott Blaszkowsky · 18 shared papers, 2013–2026 · strength 1.70
  11. Zhi Ven Fong · 10 shared papers, 2017–2026 · strength 1.58
  12. Louisa Bolm · 8 shared papers, 2020–2026 · strength 1.56
  13. Colin D. Weekes · 10 shared papers, 2019–2026 · strength 1.41
  14. Mari A. Mino-Kenudson · 15 shared papers, 2012–2025 · strength 1.39
  15. David Tsai Ting · 13 shared papers, 2015–2025 · strength 1.29
  16. Jon Michael Harrison · 8 shared papers, 2020–2026 · strength 1.22
  17. Andrew Scott Liss · 11 shared papers, 2015–2025 · strength 1.18
  18. Maximiliano Servín-Rojas · 5 shared papers, 2024–2026 · strength 1.12
  19. Vikram Deshpande · 14 shared papers, 2012–2022 · strength 1.10
  20. Marta Sandini · 8 shared papers, 2018–2025 · strength 0.88
  21. Aparna R. Parikh · 7 shared papers, 2019–2024 · strength 0.87
  22. Kim C. Honselmann · 8 shared papers, 2017–2025 · strength 0.87
  23. Theodoros P. Michelakos · 9 shared papers, 2017–2022 · strength 0.86
  24. Guoliang Qiao · 4 shared papers, 2022–2025 · strength 0.73
  25. Oliver Strobel · 4 shared papers, 2022–2025 · strength 0.69

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.